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Abstract
Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) 
classification categorizes meningiomas based on histopathological features, but emerging molecular data demon-
strate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options 
for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for 
tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment 
options are not available in part due to limited historical biological analysis and clinical trial investigation on men-
ingiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of 
interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to 
adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can 
guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are 
in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most 
up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for 
application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.
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Introduction
Meningiomas are tumors that originate from arachnoidal 
cap cells of the leptomeninges. With an incidence rate of 
8.03 per 100 000 population, they account for over a third 
of primary central nervous system (CNS) tumors, making 
them the most common primary intracranial neoplasm.1 
The incidence of meningiomas increases with age, with a 
sharp increase past 65 years, and with an aging popula-
tion this tumor is becoming increasingly more prevalent 
in the neuro-oncology community. There is a need to raise 
awareness of the gaps in knowledge and needs for this 
patient population.
Meningiomas can occur throughout the craniospinal 
axis. Multiple anatomical classifications having been pro-
posed based on the origin of dural attachment, with the 
most common locations being the convexity, olfactory 
groove, tuberculum sellae, parasagittal, parafalcine, sphen-
oid wing, petroclival, posterior fossa, or spinal.2 The 2016 
World Health Organization (WHO) classification catego-
rizes meningiomas into 3 grades and 15 histopathological 
subtypes.3 Classification of tumors as WHO grade I, II, or 
III is based on several histopathological features, including 
(i) mitotic activity (number of mitoses per 10 high-pow-
ered fields); (ii) brain invasion; and/or (iii) at least 3 other 
aggressive features such as sheet-like architecture, high 
nuclear-to-cytoplasm ratio, macronuclei, hypercellularity, 
and spontaneous necrosis. Specific histologies can ren-
der tumors as distinct grades regardless of other criteria. 
For example, tumors with predominantly clear-cell or chor-
doid histological morphology are by definition classified 
as grade II, while rhabdoid and papillary meningiomas are 
classified as grade III, although some grading controver-
sies remain for these rare subtypes.3,4 Although the extent 
of mitotic activity observed is an essential grading criter-
ion for this tumor, its detection is confounded by many fac-
tors, including sampling bias in a heterogeneous tumor, 
as well as technical factors and the experience of the path-
ologist.5 The degree of mitotic activity is an indicator of the 
proliferative potential of the tumor. Immunohistochemical 
staining of MIB-1/Ki-67 is often used to estimate the prolif-
erative potential of the tumor. Moreover, the development 
of immunohistochemical staining for phospho-histone 
H3 at serine residue 10 has provided pathologists with an 
additional sensitive and more objective marker for mitotic 
figure detection; however, use of these markers is not for-
mally included in the WHO grading system.6
The histopathological grade and the extent of resection 
of the tumor at surgery have been the most reliable clin-
ical variables correlated with tumor recurrence. However, 
the accuracy of predicting recurrence remains a consid-
erable challenge. The majority of meningiomas (80%) are 
classified as WHO grade I (“benign”) and have an indolent 
clinical course, with a 5–10% recurrence rate at 5 years.7 
Conversely, there is a near universal recurrence pattern 
(80–100%) of WHO grade III anaplastic meningiomas with 
an overall extremely poor prognosis. WHO grade II atyp-
ical tumors (5-y recurrence rate of 50%) demonstrate the 
highest variability in recurrence, making them the most 
challenging tumor type to make the best evidence-based 
management decisions.4 It is commonly recognized that 
there exists a subset of clinically aggressive meningiomas 
that display early tumor recurrence, with grading often 
outside of the predicted WHO classification. These consid-
erations highlight the need for more refined prognostica-
tion methods that facilitate individualized care.
In addition to tumor grade, the extent of resection (EOR) 
also correlates strongly with risk of tumor recurrence.8,9 The 
Simpson grade is the most widely adopted and accepted 
method to quantify the EOR in meningiomas. Simpson 
grades I–III are typically noted as gross total resection of 
tumor with varying degrees of dural and bony resection 
and resultant 9–29% estimated 10-year symptomatic recur-
rence rate. Simpson grades IV and V describe subtotal 
resections with an estimated 10-year symptomatic recur-
rence rate of 44–100%.2,8,9 Skull base meningiomas clearly 
illustrate the importance of EOR, as most are WHO grade 
I tumors but are associated with higher rates of recurrence, 
as these tumors frequently undergo subtotal resection due 
to their intimate relationship with critical neurovascular 
structures.
The current standard of care for most patients with 
symptomatic meningiomas, or those with considerable 
mass effect at the time of presentation and those that 
exhibit progressive growth on serial imaging, includes 
surgical resection of the lesion and involved dura where 
possible. Patients with WHO grade I tumors are tradition-
ally managed in follow-up with surveillance imaging. For 
WHO grade II tumors, postoperative management remains 
highly controversial regardless of the extent of resection 
or presence of residual disease. The options are upfront 
adjuvant radiation therapy to prevent or delay recurrence 
or close surveillance imaging with delayed radiation at 
time of recurrence. To date, the verdict is not clear, as there 
have been no objective or randomized studies completed 
to demonstrate the superiority of either approach, with 2 
international multi-institutional trials under way at present 
with the intent to address this critical clinical question in 
the management of WHO grade II meningiomas. For all 
grade III tumors, adjuvant radiation is strongly considered. 
With the limited efficacy and lack of any other chemother-
apeutic or targeted therapies available, the majority of 
WHO grade III tumors continue to carry an extremely poor 
prognosis.10
Despite rigorous classification by histology, morphology, 
location, and EOR, there is still significant uncertainty in 
predicting tumor behavior and risk of recurrence for an 
individual patient, and thereby patients are typically moni-
tored with long-term serial assessments. As biological data 
accumulate, molecular features will help refine prognos-
tication beyond simple classifications toward more per-
sonalized approaches, and exploit targets for therapeutic 
advantage.
Faithful tumor models are critical to understanding the 
biological underpinnings of meningioma initiation and pro-
gression and in the assessment of the efficacy of potential 
targeted therapies. Therefore, in this article, we will review 
the recently established molecular landscape of meningi-
omas along with established preclinical models that may 
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be used to better understand the biological underpinnings 
of different clinical behavior in meningiomas. Advances in 
our understanding of meningioma biology have ignited 
the development of several clinical trials utilizing novel tar-
geted therapeutics, which will be discussed in detail in a 
separate review article within this supplement (“Advances 
in Multidisciplinary Therapy for Meningiomas”).
Genomic Alterations in Meningiomas
The 2016 revisions to the WHO CNS tumor classification 
adopted a novel integrated histologic-molecular approach 
to include molecular data into classifying some primary 
brain tumors, such as gliomas and medulloblastomas.3 
However, the classification of meningiomas continues to 
be based entirely on the histopathological features, and 
this is in part due to the paucity of data in prior decades 
on the molecular landscape of meningiomas. It is only 
recently that several molecular alterations have been 
implicated in meningiomas.11–13 It is timely to digest and 
integrate the genomic findings that have the most impact 
on determining the clinical and biological behavior of men-
ingiomas, with the view to incorporate these into the future 
pathological classification of these tumors.
Copy Number Alterations
A considerable body of data exists to establish the signifi-
cance of copy number alterations (CNAs) in meningiomas. 
Somatic CNAs play a critical role in meningiomagen-
esis by dysregulating oncogene and tumor suppressor 
activity.14 Large sections of a chromosome can become 
duplicated or deleted, resulting in deviations from the 
normal diploid copy number of an allele. In many differ-
ent tumor types, specific CNAs are associated with tumor 
aggressiveness.14–17
The first cytogenetic study on meningiomas, published 
in 1967, provided a breakthrough in our understanding of 
the genetic drivers of meningiomas, showing loss of a 
G-group chromosome (either chromosome 21 or 22) in all 
tumor samples under investigation and multiple chromo-
somal aberrations in half of the samples.18 Subsequent 
studies validated the increased incidence of monosomy 22 
in meningiomas.19 These landmark studies led to the crit-
ical insight that loss of chromosome 22 is pivotal in men-
ingiomagenesis for a large subset of the tumors. Loss of 
heterozygosity (LOH) studies further narrowed the region 
of interest to chromosome 22q, which was lost in 60–70% 
of sporadic meningiomas.20,21 The incidence of 22q LOH 
increases with WHO grade, with a 50% prevalence in WHO 
grade I  tumors and 75–85% prevalence in WHO grades II 
and III tumors.21,22
Deletion of chromosome 1p is the second most com-
mon CNA identified and is mainly associated with higher 
WHO grade.21,23 Other recurrent chromosomal aberra-
tions observed in meningiomas include loss of 4p, 6q, 7p, 
9p, 10q, 11p, 14q, and 18q.21,24 These cytogenetic aberra-
tions directed researchers to explore these chromosomal 
regions for potential meningioma driver genes that are dis-
cussed further below.
Chromosomal aberrations increase in complexity 
with increasing tumor grade in meningiomas.25 In grade 
I  tumors, the only recurring chromosomal change is the 
loss of 22q; however, higher-grade tumors demonstrate 
an increased accumulation of CNAs, with grades II and III 
tumors having a median of 3.0 and 9.5, respectively, chro-
mosomal arm losses.21,24 The losses of 1p, 9p, and 14q are 
more frequently observed in higher-grade meningiomas 
that have higher rates of tumor recurrence.21,23,24,26–32 
Interestingly, grade I meningiomas with a greater burden 
of genomic disruption overall, and specifically 1p deletion, 
have a higher likelihood of progression and recurrence, 
lending evidence that there are genomic factors not cap-
tured by histopathological grade that can inform on the 
clinical behavior of meningiomas.22,30,33 Additional evi-
dence comes from findings of losses of chromosomes 1, 
14, and 22 being more prevalent in recurrent and progres-
sive tumors than de novo high-grade meningiomas.33,34 
Although profiling the CNAs in meningiomas provides val-
uable information regarding propensity for an aggressive 
clinical course, whether these alterations remain indepen-
dently prognostic after controlling for more newly discov-
ered molecular alterations discussed in sections to follow 
remains unknown, and indicates the need for more stud-
ies that utilize integrative approaches employing multiple 
“omics” platforms to compare and weigh the prognostic 
importance of genomic alterations.32
Gene Mutation Signature
Leveraging of next-generation sequencing techniques has 
led to advances in establishing the mutational signature 
of meningiomas. Over the last two decades, a substantial 
body of evidence has focused on identifying mutations in 
genes driving meningiomagenesis and aggressive tumor 
behavior (Fig. 1). Efforts to further characterize the biologi-
cal and clinical utility of these findings are ongoing, with 
several under investigation in clinical trials. Broadly the 
mutational landscape for meningiomas can be dichoto-
mized as NF2 or non-NF2 based changes.
The NF2 gene was first implicated in meningiomas after 
it was found that the inactivation of NF2, a gene encoding 
the protein neurofibromin 2 (more commonly known as 
merlin or schwannomin), resulted in the genetic tumor pre-
disposition syndrome of neurofibromatosis type 2.36,37 The 
hallmark of this genetic disease is the presence of bilateral 
vestibular schwannomas. However, roughly half of these 
patients also develop multiple meningiomas. Focal NF2 
inactivating mutations are found in 30–50% of sporadic 
meningiomas and identified in meningiomas of all 3 histo-
pathological grades.11–13,20
The NF2 gene contains 17 exons and is located on chro-
mosome 22q12.2. NF2 produces a 69  kDa protein that 
functions as a membrane-cytoskeleton scaffolding protein 
involved in the regulation of multiple pathways, including 
the mammalian hippo, PI3K/mTORC1/Akt, and receptor-
dependent mitogenic signaling pathways.38,39 NF2 muta-
tions frequently result in truncation of the protein, due to 
frameshift, nonsense, or splice-site mutations, producing a 
nonfunctional protein product.35 Consistent with Knudson’s 
2-hit hypothesis, 97% of tumors with focal NF2 mutations 
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have concomitant loss of chromosome 22q as the second 
hit.11–13,35 The loss of NF2 leads to dysregulation of these 
downstream pathways, resulting in cellular proliferation. 
NF2 mutant meningiomas indeed have a higher prolif-
eration index and larger tumor size compared with other 
genotypic variants, corroborating this proliferative path-
way dysregulation.36 Additionally, loss of NF2 gene prod-
uct leads to overexpression of focal adhesion kinase (FAK), 
resulting in increased cellular migration and invasion.40,41 
This association with overexpression of FAK may render 
these tumors sensitive to FAK inhibitors, which is currently 
under investigation in a clinical trial (NCT02523014).
It is clear that NF2 mutations and chromosome 22q loss 
play a significant role in the development of meningiomas. 
However, NF2 mutations are found in only half of all menin-
giomas.11–13,35 The development of next-generation sequenc-
ing technologies has helped usher in a renaissance in the 
field of meningioma biology, with the emergence of several 
additional genes that were recurrently mutated, with a pat-
tern that is mostly mutually exclusive of NF2 mutation.
Approximately a fifth of meningiomas harbor mutations 
of TRAF7 (tumor necrosis factor [TNF] receptor associated 
factor 7).35 TRAF7, located on chromosome 16p13, has 
been linked to modulation of the nuclear factor-kappaB 
transcription factor, activation of cellular stress pathways, 
ubiquitination of multiple cellular targets, and induction 
of apoptosis.37 Mutations in TRAF7 are mutually exclusive 
with NF2 mutations but often have a concomitant muta-
tion in v-akt murine thymoma viral oncogene homolog 
1 (AKT1) or Krüppel-like factor 4 (KLF4).12,13 AKT1 (also 
known as protein kinase B) is a central cog in the onco-
genic pathway controlled by phosphatidylinositol-3 kinase 
(PI3K), where it appears to suppress apoptosis.35 AKT1 
mutations occur in 10% of sporadic meningiomas, and 
all AKT1 mutations identified in meningioma (c.49G>A, 
AKT1E17K) lead to constitutive AKT1 activation independent 
of PI3K signaling and promote tumor growth.35,38 Similarly, 
most mutations in KLF4, a crucial regulator of cellular pro-
liferation, have been activating (c.1225A>C, KLF4K409Q),35 
resulting in tumor cell growth.39 Although AKT1 and KLF4 
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Fig.  1 Summary of established epigenomic and genomic landscape of sporadic meningiomas. DNA methylation profiling distinguishes 2 
distinct tumor subgroups with distinct risk profiles that refine risk of recurrence beyond standard-of-care histopathological grading and are 
associated with typical known mutations.
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mutations can both concomitantly occur with TRAF7, they 
are mutually exclusive of each other.35,40
There are many significant clinical correlations in the 
mutational profile of meningiomas. For example, TRAF7, 
AKT1, and KLF4 mutations are almost exclusively observed 
in WHO grade I  meningiomas.11–13,35 Moreover, secretory 
meningiomas invariably harbor concomitant TRAF7 and 
KLF4K409Q mutations,41 and similarly, meningiomas with 
AKT1E17K mutation tend to have meningothelial and transi-
tional histopathological morphology.35,42 A strong correla-
tion with tumor location has also been demonstrated, with 
TRAF7, AKT1, and KLF4 mutations more commonly located 
in anterior and middle fossa skull base meningiomas.11–13,35
The hedgehog (Hh) signaling pathway has also been 
implicated in the development of a subset of meningi-
omas, specifically via mutations in Smoothened (SMO; 
frizzled family receptors) and suppressor of fused homolog 
(SUFU) genes. SMO is a G-protein coupled-like receptor 
and part of the Hh signaling pathway. Mutations in this 
gene are found in 3–6% of meningiomas and are mutu-
ally exclusive with NF2, and other non-NF2 mutations.35,40 
SMO-mutant meningiomas are exclusively observed in 
WHO grade I meningiomas and occur in the anterior mid-
line skull base.35,42 Most notably, the SMO mutation is 
one of the few targetable genetic alterations identified in 
meningiomas to date. A  clinical trial with vismodegib, a 
competitive antagonist of the SMO receptor, is currently 
ongoing (NCT02523014). SUFU is also a member of the Hh 
family and mutated in less than 1% of sporadic meningi-
omas. However, familial cases of meningiomas are known 
to harbor germline mutations in SUFU.12 Details regarding 
clinical trials can be found in “Advances in Multidisciplinary 
Therapy for Meningiomas” within this supplement.
Another potential targetable mutation is phosphati-
dylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
alpha (PIK3CA). This mutation is found in 4–7% of meningi-
omas.35,40,43 PIK3CA is a known oncogene located on chro-
mosome 3q26.3 that is mutated in approximately 15% of 
all human cancers.43 PIK3CAH1047R and PIK3CAE545K, which 
are two of many mutations observed in PIK3CA, constitu-
tively phosphorylate and activate AKT1.44 PIK3CA muta-
tions are mutually exclusive of NF2, SMO, and AKT1 and in 
very few cases co-occur with TRAF7 or KLF4 mutations.35,40
RNA polymerase II (POLR2A), the protein that mediates 
transcription of all protein-coding genes in eukaryotes, 
has been identified in approximately 6% of grade I menin-
giomas. The recurrent somatic hotspot mutations include 
G403K as well as in-frame deletion of residues Leu438 and 
His439.12 The functional role of POLR2A mutations in tumor 
development is not well understood. Similar to other non-
NF2 meningiomas, POLR2A-mutant meningiomas are 
exclusively WHO grade I tumors that are most likely to be 
found in anterior skull base (tuberculum sellae) tumors 
and tend to harbor a meningothelial histopathological 
morphology.11–13,35
In addition to gene mutations that affect single factor 
dysregulation, disruptions of the machinery needed for 
gene processing are emerging as processes that are cen-
tral to tumor progression. Converging lines of evidence 
suggest an essential role for the Switch/sucrose non-
fermentable (SWI/SNF) chromatin-remodeling complex 
in meningioma formation and aggressiveness. Several 
families with multiple meningiomas and schwannomas 
harbor germline mutations in the SWI/SNF core complex 
unit SMARCB1.45,46 However, SMARCB1 mutations have 
also been observed in a small subset of sporadic grade 
I and grade II meningiomas, concurrently with NF2 muta-
tions.11,47 Loss-of-function mutations in another core sub-
unit of the SWI/SNF complex, SMARCE1, are a molecular 
signature of the clear-cell subtype of meningiomas.48–51
Overall, mutations in SWI/SNF complex genes are 
observed at higher frequency in anaplastic meningiomas 
compared with grades I  and II meningiomas, and hence 
are associated with poor prognoses.52 Furthermore, high-
grade meningiomas demonstrate upregulation of the 
polycomb repressive complex 2 (PRC2) and its catalytic 
domain, which function in balance with the SWI/SNF com-
plex.47 Taken together, loss-of-function mutations in core 
members of the SWI/SNF complex and upregulation of its 
antagonist increasingly reveal the critical role of chromatin 
regulation in meningiomas.
Inactivating germline and somatic mutations in the 
tumor suppressor breast cancer (BRCA)–associated pro-
tein 1 (BAP1) gene have been identified in a rare subset of 
aggressive meningiomas with rhabdoid morphology.53–55 
Patients with germline BAP1 mutations are predisposed to 
multiple tumors, including melanoma, mesothelioma, and 
other cancers; identification of a germline BAP1 mutation, 
therefore, calls for increased vigilance in cancer surveil-
lance in individuals who harbor this mutation. Mechanisms 
of BAP1 inactivation are diverse, including focal deletion, 
nonsense mutation, frameshift mutation, and intrachro-
mosomal fusion. Additional loss of chromosome 3p, which 
harbors BAP1, results in full inactivation of this tumor sup-
pressor. Importantly, BAP1-deficient mesothelioma tumor 
cells have been demonstrated to be sensitive to inhibitors 
of enhancer of zeste homolog 2, presenting an opportu-
nity for potential pharmacologic inhibition in BAP1-mutant 
meningiomas.56
There is increasing awareness of the importance of 
studying the noncoding regions that affect gene expres-
sion. Similarly, in meningiomas, there has been recent 
recognition of the role of mutations in the telomerase 
reverse transcriptase (TERT) promoter. TERT maintains 
the length of the telomere ends by addition of a highly 
conserved sequence of TTAGGG at the end of each chro-
mosome. Somatic cells normally repress TERT, leading 
to senescence. Mutations in the promoter region increase 
E-twenty-six transcription factor binding and upregulate 
TERT expression.57 The constitutive expression of TERT 
results in the immortalization of the cancer cell. TERT 
promoter mutations, occurring specifically in the hotspot 
regions C228T and C250T, are detected in 6.5–11% of men-
ingiomas.58,59 In fact, TERT promoter mutations may be 
among the most common mutations in all human cancers, 
suggesting that presence of TERT promoter mutation is a 
potential biomarker for meningiomas with a higher likeli-
hood of clinically aggressive behavior that exhibit higher 
rates of recurrence and shorter time to progression.57–59 
TERT promoter mutations have been observed in both 
NF2-mutated and NF2-wildtype tumors; however, correla-
tions with other genetic alterations have not been clearly 
established.58,59 Certainly, the presence of TERT promoter 
mutations should trigger clinicians to monitor the patient 
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closely for transformation to a more aggressive tumor 
and potentially consider adjuvant intervention early in the 
course of the disease.
The identification of novel actionable molecular altera-
tions that are drivers of tumor growth gives rise to the 
opportunity for developing targeted therapies toward 
genetic subsets of meningiomas. In keeping with this, 
several clinical trials—such as a phase II multicenter trial 
(NCT02523014) studying the effects of SMO receptor and 
FAK inhibitors on progression-free survival in meningi-
omas with SMO or NF2 mutations, respectively—are cur-
rently under way and will be discussed in more detail in 
our companion review article within this supplement, 
“Advances in Multidisciplinary Therapy for Meningiomas.”
The above highlights a key critical observation that while 
a high percentage of meningiomas have NF2 mutations, 
non-NF2 mutations identified each occur with a lower fre-
quency than NF2 mutation. Interestingly, mutational signa-
tures with driver mutations described above account for 
the vast majority (>90%) of meningiomas. While targeting 
each of these potentially druggable individual mutations 
offers invaluable treatment potential, looking to aberra-
tions outside of the mutational landscape of meningiomas 
is essential, as few of the mutational alterations have been 
correlated with aggressive tumor behavior. Epigenetic 
alterations have gained considerable attention in the abil-
ity to classify and diagnose brain tumors with precision 
beyond standard-of-care clinical practice,60 and therefore 
epigenetic changes may also be the key to the next genera-
tion of diagnostics and therapeutics for meningiomas.
Epigenomic Alterations in Meningioma
DNA Methylation
DNA methylation is one of the best studied epigenetic 
regulators of gene transcription and plays a significant role 
in cancer biology. Methylation of DNA is catalyzed by the 
DNA methyltransferase (DNMT) family of enzymes, with 
DNMT3A and DNMT3B catalyzing de novo DNA methyla-
tion and DNMT1 mediating both de novo and maintenance 
methylation of DNA.61 Global DNA hypomethylation and 
focal DNA hypermethylation are associated with tumori-
genesis.62 The most notable genes reported with differen-
tial DNA methylation in meningiomas are tissue inhibitor 
of metalloproteinase 3 (TIMP3), cyclin-dependent kinase 
inhibitor 2A (CDKN2A), and tumor protein 73 (TP73), which 
are hypermethylated in at least 10% of cases.63 TIMP3 
hypermethylation results in transcriptional downregula-
tion and inhibits its tumor suppressor properties.64 TIMP3 
is frequently hypermethylated in higher-grade meningi-
omas, with a frequency of 40–60% in grade III tumors and 
associated with a shorter time to recurrence.63,65 In add-
ition, TIMP3 is found on chromosome 22q12, and almost 
all cases with TIMP3 hypermethylation had a concurrent 
allelic loss of 22q.65 Seventy to eighty percent of high-
grade tumors have TP73 promoter methylation, and this 
is not commonly seen in grade I tumors,66 suggesting the 
potential utility of TP73 promoter methylation as a bio-
marker for meningiomas of higher grade.
There has been an emerging recognition in the value of 
leveraging global methylation signatures of brain tumors 
beyond single gene methylation analysis.60 In this past 
year, 2 studies have provided evidence for the importance 
of global methylation profiles in molecular subclassifica-
tion of meningiomas.67,68 Olar et  al in 2017 first demon-
strated that unsupervised clustering of DNA methylation 
data classified meningiomas into 2 distinct subgroups 
associated with recurrence-free survival. After adjusting 
for clinical factors, such as WHO grade and Simpson grade, 
a statistically significant association between DNA methyl-
ation subclasses and tumor recurrence was maintained.67 
Similarly, Sahm et al in 2017 identified 2 major groups and 
6 subgroups of meningiomas based on unsupervised clus-
tering of DNA methylation data, with significantly differ-
ent genomic makeup and clinical behaviors. Interestingly, 
most non-NF2 meningiomas clustered together into a sin-
gle benign subgroup, further supporting the benign nature 
of these tumors and the difference from NF2-mutated 
tumors.68 These initial efforts suggest that epigenetic sig-
natures may have strong clinical associations with tumor 
recurrence, to a more significant extent than can be cor-
related with mutational genetic analysis (Fig. 1), and that 
these may be applied clinically for individual patients. An 
additional manifestation of the importance of epigenetic 
changes in meningioma clinical behavior was recently 
shown, describing an increased risk of recurrence in 
tumors that show a loss of histone H3K27 trimethylation.69
Given the distinct clinical behavior of meningiomas 
based on global methylation signature, a validated methy-
lome-based predictor for tumor recurrence would leverage 
knowledge gained from methylation analysis and trans-
late it into clinical application to facilitate decision making 
regarding need for adjuvant therapy beyond standard of 
care. Additionally, conceivably, use of epigenetic modi-
fiers to convert a poor prognosis meningioma to a more 
favorable methylation profile would be transformative in 
management options available for meningiomas.
Micro-RNA
Over the past decade, interest in the role of micro-RNA 
(miRNA) in carcinogenesis has been rapidly growing. 
MiRNAs are a subset of small (~22 nucleotides) noncoding 
RNAs that posttranscriptionally regulate the expression 
of target mRNA. The surge of miRNA research has been 
lagging in meningiomas, with only a few studies explor-
ing the role of this epigenetic change in meningiomas. 
MiRNA-200a, which targets B-catenin, is downregulated 
approximately 25-fold in meningiomas and leads to abnor-
mal WNT/B-catenin pathway signaling.70 MiRNA expres-
sion patterns can differentiate between tumors of different 
grades and those with different mutations (NF2 and non-
NF2). They are also correlated with tumor growth.71 For 
example, miRNA-145 expression is markedly decreased 
in higher-grade tumors, and overexpression in cell lines 
has shown reduced proliferation and tumor growth.72 In 
addition to this, tumors that overexpress miRNA-109a and 
those that underexpress miRNA-29c-3p and miR-219-5p 
have been shown to have higher recurrence rates in men-
ingiomas.73 Similar to miRNAs, long-noncoding RNAs 
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(lncRNAs) are being explored as potential factors that can 
elucidate biological behavior of meningiomas. The ultimate 
clinical application of miRNAs and lncRNAs in understand-
ing clinical behavior of meningiomas and possible exploit-
ation as therapeutic prospects has yet to be established.
Transcriptomic Signatures in 
Meningioma
Given that signatures of epigenetic alterations, such as 
DNA methylation, have defined subgroups of meningi-
omas with important clinical implications, it is logical to 
investigate whether these signatures transcend to gene 
expression profiling to also recapitulate these important 
findings. Microarray gene expression analysis has iden-
tified potential biomarkers to distinguish benign men-
ingiomas from those with higher risk of progression or 
recurrence. A  37-gene signature was identified to corre-
late well with overall survival,74 and recently an 18-gene 
signature was found to correlate with progression-free 
survival after validation in an independent cohort.75 These 
genes were found to be involved in pathways involving 
normal embryonic development, cell proliferation/inva-
sion, and angiogenesis, among others. In addition to this, 
increased transglutaminase 2 (TGM2) expression has been 
described in higher-grade meningioma76 and the deleted in 
colorectal cancer (DCC) gene, which encodes a transmem-
brane receptor for netrin-1 and has also been suggested 
to be a marker for risk of meningioma progression.77 Most 
gene expression studies have been limited by their small 
sample size (10–50 tumors), with minimal overlap in the 
candidate genes identified between studies,64,74,76–80 and 
therefore further studies are needed to validate potential 
gene expression biomarkers.
Proteomic Signatures in Meningiomas
Interest in broad protein profile screening in cancers has 
garnered significant momentum in the post-genome era. 
Proteomic-based approaches have tremendous clinical 
impact, as results may be validated via immunohisto-
chemistry, allowing immediate facilitation for clinical use. 
Similar to transcriptomic analyses, proteomic research 
remains limited in meningiomas, with only 2 previous pro-
teomic studies having established differential proteomic 
profiles between meningioma grades. Okamoto et al per-
formed a comparative analysis of different grade menin-
giomas analyzing pure populations of tumor cells via gel 
electrophoresis combined with mass spectrometry and 
identified 15 proteins that were differentially expressed 
between benign and atypical tumors and 9 proteins that 
were differentially expressed between atypical and malig-
nant tumors. Their analysis did not, however, consider 
a normal control, which would ideally be arachnoid cap 
cells. Furthermore, only one of the identified proteins was 
probed and validated by immunohistochemistry.81 Using 
more powerful high-throughput approaches (iTRAQ-based 
proteomics), Sharma et  al identified over 2000 differen-
tially expressed proteins in meningiomas associated with 
diverse signaling pathways such as integrin, Wnt, Ras, epi-
dermal growth factor receptor, and Gardner-Rasheed feline 
sarcoma (FGR).82 Other proteomic studies have focused on 
grade I meningiomas and their differential expression to 
arachnoid tissue adjacent to tumor, identifying only 17 and 
26 proteins to be downregulated and upregulated, respec-
tively.83 Saydam et al performed proteomic analyses from 
a benign meningioma cell line and primary arachnoidal 
cells focusing on members of the minichromosome main-
tenance (MCM) family.84 Recognizing the importance of 
understanding the implication of genomic alterations in 
how it alters protein function, the field of proteomics has 
the potential to provide the next advance in knowledge of 
meningioma biology and translation to diagnostic, predic-
tive, and therapeutic directions.
Molecular Alterations in Distinct 
Meningioma Populations
Pediatric Meningiomas
Meningiomas are exceedingly rare among children and 
adolescents (0–21 y), accounting for 0.4–4.1% of all pedi-
atric brain tumors.85 One of the most intriguing differences 
from adult tumors is the frequent occurrence of aggressive 
histological subtypes.86–88 Rhabdoid or papillary menin-
giomas are observed in up to 13% of patients,86 and ana-
plastic tumors are diagnosed in about 6% of patients.87 
Additionally, clear-cell meningiomas are found at a higher 
incidence in children compared with adults, perhaps as a 
consequence of germline SMARCE1 mutations, discussed 
in the above sections.86 Despite the greater proportion of 
higher-grade tumors, the long-term results for pediat-
ric meningiomas are favorable, which raises questions 
regarding the relevance of aggressive histopathological 
features in meningiomas of this age group.89 An explora-
tory study using targeted Sanger sequencing did not iden-
tify the typical mutations found in adult meningiomas, 
such as mutations in SMO, AKT, KLF4, TRAF7 (exon 17), 
and TERT promoter.90 Of the 40 cases studied in this series, 
NF2 deletions were observed in 30 patients (75%). Future 
studies focusing on meningiomas should attempt to dis-
cover novel non-NF2 alterations, which may help explain 
both the predominance of specific histological subtypes as 
well as the lack of common non-NF2-associated mutations.
Radiation-Induced Meningiomas
Although cancer treatments have been advancing such 
that children are surviving their primary cancer in greater 
proportions, long-term complications of craniospinal radi-
ation in the form of additional neoplasms in adult life are 
also increasing in proportion. Radiation-induced meningi-
omas (RIMs) are the most common brain neoplasm sec-
ondary to radiation and typically occur 10–30 years after 
radiotherapy.91,92 Children who have received only 1–2 Gy 
of radiation are at a 9.5-fold increased risk of developing a 
meningioma in their lifetime.93 These tumors exhibit con-
cerning histopathological features, such as hypercellular-
ity, pleomorphic nuclei, and increased mitotic index,91,94 
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and in line with this, display aggressive clinical phenotype 
with increased tumor recurrence rates.91,93,94 The muta-
tional signature of RIMs is distinct from their sporadic 
counterparts.91,95 RIMs invariably have a more complex 
cytogenetic architecture, with higher rates of recurrent 
losses of chromosomes 1p and 22q in comparison to 
sporadic meningiomas.91 It is possible that the radiation 
therapy triggers double-stranded DNA breaks and subse-
quent error-prone repair, resulting in the increased CNAs 
observed in these tumors. Interestingly, the rates of NF2 
mutations are significantly lower in RIMs in comparison 
to sporadic meningiomas (6% vs 30–50%).91,95,96 However, 
integrated multiplatform genomic interrogation of RIMs 
has uncovered promiscuous NF2 intronic genomic rear-
rangements in 40% of cases, exhibiting fusions with intra- 
and interchromosomal regions.95 Moreover, druggable 
targets found in sporadic meningiomas, such as AKT1 and 
SMO, were not observed in RIMs,95 highlighting that the 
biology of these tumors is distinct from sporadic counter-
parts. Additional investigations are needed to understand 
the risks for RIM formation as well as therapies that can be 
implemented early before tumor formation or progression.
Faithful Preclinical Models of 
Meningiomas
Tumor models are critical to facilitate investigation of 
mechanisms behind tumor initiation and progression as 
well as for testing and validation of new therapeutic strat-
egies for clinical translation. Models are relevant if they 
recapitulate the disease as seen in humans from both a 
histological and a molecular perspective. To date, limited 
established preclinical models, both xenograft mouse 
models and genetically engineered models, have been 
developed for meningiomas and may be used to help 
translate discoveries for clinical utility.
Xenograft Models
The first reports of successful heterotopic engraftment 
of meningioma cells into athymic nude mice were in the 
1970s.97,98 Since then, orthotopic xenograft models using 
either established cell lines, such as IOMM-Lee, or patient-
derived xenograft (PDX) cells, have been used to fill large 
gaps in our understanding of meningioma biology, as well 
as to test drugs aimed at improving clinical outcomes.
Since detailed molecular analyses of patient meningi-
oma specimens have only recently been completed, it is of 
little surprise that the genomics of PDX models have yet to 
be rigorously characterized to determine if they faithfully 
reproduce the features of the original tumors. Rath et  al 
compared their meningioma PDX model with the paren-
tal grade II tumor and found that their PDX model mostly 
retained the original tumor’s chromosome profile, includ-
ing 9p21.3 deletion and gains in chromosomes 3, 7, and 
9, as well as intact NF2. Furthermore, the histologic and 
molecular features of the original tumor and in vitro pas-
sages were also successfully recapitulated in the subcuta-
neous flank xenografts.99
Established cell lines have been used to generate 
orthotopic xenograft models in the absence of patient-
derived cells. The catalogue of available established cell 
lines in meningiomas, however, is limited. Perhaps the 
best characterized is the Ben-Men1 line, which is derived 
from a WHO grade I  meningothelial meningioma with 
an NF2 mutation. IOMM-Lee and CH157-MN are both 
derived from higher-grade meningiomas, and IOMM-
Lee was derived from a tumor that did not contain LOH 
of chromosome 22. Next-generation sequencing has 
demonstrated that cell lines retain their parental molec-
ular features. For example, CH157 and Ben-Men1 harbor 
NF2 deletions like their parental tumors,100,101 whereas 
IOMM-Lee cells have intact NF2.102,103 CH157-MN and 
IOMM-Lee cells, both of which are harvested from 
aggressive primary tumors, also harbor TERT promoter 
mutations and harbor a copy number profile that is 
similar to malignant meningiomas. In addition to this, 
HBL-52 cell lines harbor the canonical TRAF7 mutation, 
potentially rendering them useful to studies targeting 
the TRAF7 mutation. However, cell lines carrying the 
other known non-NF2 mutations (SMO, AKT1, KLF4) 
have not been identified, and therefore, in vitro mod-
els that recapitulate these oncogenic alterations are in 
critical need.
Detailed genomic and epigenomic profiling of menin-
gioma PDX and their matching original patient-derived 
tumors are critical next steps in advancing our under-
standing of meningioma biology and has a high likelihood 
of identifying novel mechanisms of aggressive tumor 
behavior that may be vulnerable to innovative treatment 
strategies.
Genetically Engineered Mouse Models
Although xenograft models have clear advantages, 
implantation of cells disrupts the tumor microenviron-
ment, which may pose difficulties when evaluating treat-
ment resistance. Genetically engineered models can 
accurately mimic the histology and clinical behavior of 
human tumors without disrupting the microenviron-
ment and are gaining traction in meningiomas. Direct 
intrathecal injection of recombinant Cre adenovirus into 
NF2loxP/loxP mice has resulted in a model of mosaic NF2-
driven benign meningiomas.104 Adenovirus Cre-mediated 
Cdkn2ab deletions in addition to the above NF2 biallelic 
inactivation have resulted in mice with a greater pro-
portion of aggressive tumors with shorter overall sur-
vival and higher-grade tumors by histology.105 Although 
aggressive genetically engineered meningioma models 
can be developed, the alterations that are both necessary 
and sufficient to generate higher-grade, aggressive men-
ingiomas remain unknown, and therefore the phenotype 
of the models developed can be variable. In addition to 
this, the rate of tumor induction is low in the established 
genetically engineered models, and a substantial period 
of time is needed until tumor burden is recognized. Lastly, 
due to alterations occurring in precursor cells, genetically 
engineered models do not recapitulate the phenotype of 
adult-onset meningiomas.
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Preclinical Models: Junction of Genomics and 
Therapeutics
One of the earliest examples of using meningioma PDX 
to evaluate novel therapies in meningioma PDX was the 
use of the antiprogesterone RU-38486 against a primary 
human meningioma implanted into the subcutaneous 
flank of nu/nu Balb C mice that demonstrated inhibition of 
tumor growth in all mice.106 Similarly, because meningi-
omas often express estrogen and progesterone receptors, 
and high fatty acid synthase (FAS) had been associated 
with expression of such hormone-driven tumor cells, 
Fig. 2 Sample integrated molecular-histopathological report. These reports can be used to facilitate communication of impactful histological 
(WHO grade, number of mitoses, specific histologies, and criteria) and key molecular findings (DNA methylation class, clinically relevant CNAs, 
and mutations).
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IOMM-Lee flank PDXs were treated with the FAS inhibi-
tor cerulenin, which resulted in a 30% reduction in tumor 
mass.107 Recently it has been shown that merlin-deficient 
cells seem to be primarily dependent on the fatty acid mal-
onyl-CoA for cellular metabolism, rendering grade I  pri-
mary meningioma cells with NF2 deletion highly sensitive 
to the FAS inhibitor GSK2194069.108
Only a few preclinical studies using meningioma PDX 
models have generated data that can be linked to clini-
cal trial concepts. For example, although several studies, 
using primary and IOMM-Lee meningioma flank xeno-
grafts, have suggested that hydroxyurea and calcium 
channel blockers may bear therapeutic potential,109,110 the 
combination of hydroxyurea and verapamil was ineffec-
tive in a phase I/II trial of treatment-resistant meningi-
omas (NCT00706810).111 Similarly, the cyclooxygenase-2 
inhibitor celecoxib showed early promise against several 
subcutaneous flank PDX models, including IOMM-Lee, 
CH157-MN, and primary grade I meningioma.112 However, 
subsequent testing of intracranial PDX, developed from 
4 separate primary meningiomas, showed no antitu-
mor activity,113 and thus further clinical studies were 
not pursued. Given the strong association of epigenetic 
alterations with clinically relevant subtypes of meningi-
omas, the histone deacetylase inhibitor AR-42 had been 
tested in an intracranial Ben-Men1 PDX and was shown 
to inhibit pAkt, several cyclin-dependent kinases, and in 
vivo growth.102 This work has led to an ongoing proof-of-
concept phase 0 clinical trial aimed at studying concen-
tration, pAkt, and p16INKA after 3 weeks of AR-42 intake 
in patients with meningiomas (NCT02282917). Use of the 
mammalian target of rapamycin (mTOR) inhibitors siroli-
mus and everolimus has demonstrated reduced in vivo 
growth of IOMM-Lee cells implanted subcutaneously or 
intracranially.114 These findings contributed to the ini-
tiation of ongoing clinical trials aimed at evaluating the 
mTOR complex 1/2 inhibitor AZD2014 against recurrent 
sporadic grades II–III meningiomas (NCT03071874) and 
NF2-associated meningiomas (NCT02831257). Lastly, 
irinotecan, a topoisomerase inhibitor, was successfully 
used to arrest the subcutaneous growth of IOMM-Lee 
PDX.115 Four clinical trials have been completed but have 
not yet reported on topoisomerase inhibitor efficacy in 
refractory solid tumors, which included meningioma.
Despite disappointing results so far, some newer PDX-
based studies offer hope for a new series of clinical trials, 
including those targeted against key molecular alterations 
in meningiomas. A screen of 11 chemotherapeutic agents 
commonly used against a variety of cancers, including 
mainstays such as temozolomide, platinum-based drugs, 
and methotrexate, has identified gemcitabine as being 
particularly effective against grade II M-16-N and grade III 
HKBMM meningioma cells in vitro and in vivo.116 A grade III 
anaplastic meningioma PDX model has also been shown 
to be sensitive to an oncolytic herpesvirus.117 Protein phos-
phatase 2A (PP2A) inhibitor LB-100 doubled the survival 
benefit of radiotherapy in mice with intracranial xenografts 
of human IOMM-Lee immortalized meningioma cells.118 As 
merlin inhibits p21-activated kinase 1 (Pak1), Pak inhibitors 
have also been shown to be able to suppress the growth 
of NF2-deficient meningioma KT21 and Ben-Men PDXs.119 
Immune-based therapies are more difficult to test in PDX 
models, which are mostly based on immunocompromised 
mice. However, immunocompetent mice with humanized 
immune systems could be employed to study meningioma 
immunotherapies, as has been done in gliomas.120
Conclusions
Meningiomas are the most common primary brain tumor. 
However, they have not benefited from extensive research 
and investigative analysis. There have been outstanding 
recent large-scale genomic studies in meningiomas that 
have helped improve our understanding of the biology of 
meningiomas in addition to raising awareness of the need 
for further research on this tumor type. Translation of the 
emerging molecular, in particular genomic/epigenomic, 
knowledge into clinical management remains in its infancy 
and provides a tremendous opportunity to leverage and 
explore improved diagnostics of molecular pathology, 
predictive algorithms, and therapeutic strategies for men-
ingiomas. Integrated histomolecular pathology reports 
that outline histopathological diagnosis and associated 
clinically important genetic and epigenetic changes within 
tumors will facilitate communication of crucial actionable 
findings between pathologists and clinicians and are a key 
step for the advancement of care of patients with meningi-
omas (Fig.  2). A  comprehensive integrated multiplatform 
genomic and epigenomic characterization of clinically 
aggressive meningiomas will facilitate comprehensive and 
personalized care ranging from patient counseling to ulti-
mately advancing treatment. Most of the available literature 
on meningioma genomics is centered around WHO grade 
I meningiomas, and those studies focusing on anaplastic or 
malignant meningioma have small cohort sizes. Harnessing 
collaborative science, the interdisciplinary team of clini-
cians and scientists within the International Consortium on 
Meningiomas (ICOM) will allow building of the critical large 
cohort sizes necessary for analysis as well as the merging of 
expertise, knowledge, and efforts to fill the gaps in knowl-
edge needed to improve the management of meningiomas.
Recommendations
To advance our understanding of the molecular biology of 
meningiomas, ICOM recommends:
• Ongoing collaboration and advocacy with the World 
Health Organization to integrate molecular alterations 
with the histopathological diagnosis of meningiomas 
(Fig. 2)
• Stronger emphasis on studying the epigenomic land-
scape of meningiomas to understand better critical alter-
ations driving clinically aggressive behavior
• Incorporating genomic/epigenomic and key clinical 
factors into tools that may be used to establish pre-
dictors of tumor behavior and refine the precision 
in prognostication of meningiomas beyond general 
classifications
• Resource allocation and focused funding of interdiscip-
linary collaborative efforts focusing on uncovering the 
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molecular alterations of higher-grade and aggressive 
meningiomas
• Building faithful and reproducible strong preclinical 
models that recapitulate the human disease from a his-
topathological, molecular, and clinical aspect, allowing 
for rapid translation of discoveries to the clinic
Funding
The collaborative effort of the International Consortium on 
Meningiomas is supported by The Brain Tumour Charity Quest 
for Cures: Collaborative Team Award and the Canadian Institute 
of Health Research.
Acknowledgments
We would like to acknowledge João-Paulo Almeida and Shirin 
Karimi for their assistance with the endoscopic and histopatho-
logical images found on the front cover of the journal.
Conflict of interest statement. The authors have no personal, 
financial, or institutional interest in any of the drugs, materials, 
or devices described in this article.
Authorship statement. The generation of all manuscripts 
has been supported by the membership of the consortium, 
which at the time of supplement generation includes:
Kenneth Aldape, Karolyn Au, Jill Barnhartz-Sloan, Wenya 
Linda Bi, Priscilla K. Brastianos, Nicholas Butowski, Carlos 
Carlotti, Michael D. Cusimano, Francesco DiMeco, Katharine 
Drummond, Ian F. Dunn, Evanthia Galanis, Caterina Giannini, 
Roland Goldbrunner, Brent Griffith, Rintaro Hashizume, C. Oliver 
Hanemann, Christel Herold-Mende, Craig Horbinski, Raymond 
Y. Huang, David James, Michael D. Jenkinson, Christine 
Jungk, Timothy J. Kaufman, Boris Krischek, Daniel Lachance, 
Christian Lafougère, Ian Lee, Jeff C. Liu, Yasin Mamatjan, 
Alireza Mansouri, Christian Mawrin, Michael McDermott, 
David Munoz, Farshad Nassiri, Houtan Noushmehr, Ho-Keung 
Ng, Arie Perry, Farhad Pirouzmand, Laila M Poisson, Bianca 
Pollo, David Raleigh, Felix Sahm, Andrea Saladino, Thomas 
Santarius, Christian Schichor, David Schultz, Nils O. Schmidt, 
Warren Selman, Andrew Sloan, Julian Spears, James Snyder, 
Suganth Suppiah, Ghazaleh Tabatabai, Marcos Tatagiba, 
Daniela Tirapelli, Joerg C. Tonn, Derek Tsang, Michael A. 
Vogelbaum, Andreas von Deimling, Patrick Y. Wen, Tobias 
Walbert, Manfred Westphal, Adriana M. Workewych, Gelareh 
Zadeh.
Sponsorship statement. This supplement was supported by 
an unrestricted grant from the MacFeeters Hamilton Neuro-
Oncology Program at the Princess Margaret Cancer Center and 
by the Dr. Mary Hunter Brain Tumor Research Funds from the 
Toronto General & Western Hospital Foundation.
References
1. Ostrom QT, Gittleman H, Liao P, et  al. CBTRUS statistical report: 
primary brain and other central nervous system tumors diag-
nosed in the United States in 2010–2014. Neuro-Oncol. 
2017;19(suppl_5):v1–v88.
2. Gallagher MJ, Jenkinson MD, Brodbelt AR, Mills SJ, Chavredakis E. 
WHO grade 1 meningioma recurrence: are location and Simpson grade 
still relevant? Clin Neurol Neurosurg. 2016;141:117–121.
3. Louis DN, Perry A, Reifenberger G, et  al. The 2016 World Health 
Organization classification of tumors of the central nervous system: a 
summary. Acta Neuropathol. 2016;131(6):803–820.
4. Vaubel RA, Chen SG, Raleigh DR, et  al. Meningiomas with rhabdoid 
features lacking other histologic features of malignancy: a study of 
44 cases and review of the literature. J Neuropathol Exp Neurol. 
2016;75(1):44–52.
5. Jenkinson MD, Santarius T, Zadeh G, Aldape KD. Atypical meningi-
oma—is it time to standardize surgical sampling techniques? Neuro 
Oncol. 2017;19(3):453–454.
6. Olar A, Wani KM, Sulman EP, et  al. Mitotic index is an independent 
predictor of recurrence-free survival in meningioma. Brain Pathol. 
2015;25(3):266–275.
7. Adeberg S, Hartmann C, Welzel T, et al. Long-term outcome after radio-
therapy in patients with atypical and malignant meningiomas—clinical 
results in 85 patients treated in a single institution leading to optimized 
guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys. 
2012;83(3):859–864.
8. Simpson D. The recurrence of intracranial meningiomas after surgical 
treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22–39.
9. Gousias K, Schramm J, Simon M. The Simpson grading revisited: 
aggressive surgery and its place in modern meningioma management. J 
Neurosurg. 2016;125(3):551–560.
10. Goldbrunner R, Minniti G, Preusser M, et  al. EANO guidelines 
for the diagnosis and treatment of meningiomas. Lancet Oncol. 
2016;17(9):e383–e391.
11. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing 
of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat 
Genet. 2013;45(3):285–289.
12. Clark VE, Harmancı AS, Bai H, et  al. Recurrent somatic mutations 
in POLR2A define a distinct subset of meningiomas. Nat Genet. 
2016;48(10):1253–1259.
13. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 
meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. 
Science. 2013;339(6123):1077–1080.
14. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic 
copy number alteration. Nat Genet. 2013;45(10):1134–1140.
15. Cheng I, Levin AM, Tai YC, et al. Copy number alterations in prostate 
tumors and disease aggressiveness. Genes Chromosomes Cancer. 
2012;51(1):66–76.
16. Beroukhim R, Mermel CH, Porter D, et  al. The landscape of som-
atic copy-number alteration across human cancers. Nature. 
2010;463(7283):899–905.
17. Zhang Y, Martens JWM, Yu JX, et  al. Copy number alterations that 
predict metastatic capability of human breast cancer. Cancer Res. 
2009;69(9):3795–3801.
18. Zang KD, Singer H. Chromosomal consitution of meningiomas. Nature. 
1967;216(5110):84–85.
19. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular 
genetic approach to human meningioma: loss of genes on chromosome 
22. Proc Natl Acad Sci U S A. 1987;84(15):5419–5423.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/21/Supplem
ent_1/i4/5289366 by johns hopkins university user on 03 July 2019
i15Suppiah et al. Molecular landscape of sporadic meningiomas
N
eu
ro-
O
n
colog
y
20. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the com-
plete inactivation of the NF2 gene in the majority of sporadic meningi-
omas. Nat Genet. 1994;6(2):180–184.
21. Lee Y, Liu J, Patel S, et al. Genomic landscape of meningiomas. Brain 
Pathol. 2010;20(4):751–762.
22. Bi WL, Greenwald NF, Abedalthagafi M, et al. Erratum: genomic land-
scape of high-grade meningiomas. NPJ Genom Med. 2017;2:26.
23. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-
Demasters BK, Perry A. Chromosome 1p and 14q FISH analysis in 
clinicopathologic subsets of meningioma: diagnostic and prognostic 
implications. J Neuropathol Exp Neurol. 2001;60(6):628–636.
24. Zang KD. Meningioma: a cytogenetic model of a complex benign human 
tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet. 
2001;93(3-4):207–220.
25. Abedalthagafi MS, Merrill PH, Bi WL, et  al. Angiomatous menin-
giomas have a distinct genetic profile with multiple chromosomal 
polysomies including polysomy of chromosome 5. Oncotarget. 
2014;5(21):10596–10606.
26. López-Ginés C, Cerdá-Nicolás M, Gil-Benso R, Barcia-Salorio JL, 
Llombart-Bosch A. Loss of 1p in recurrent meningiomas: a comparative 
study in successive recurrences by cytogenetics and fluorescence in situ 
hybridization. Cancer Genet Cytogenet. 2001;125(2):119–124.
27. Ketter R, Henn W, Niedermayer I, et  al. Predictive value of pro-
gression-associated chromosomal aberrations for the prognosis 
of meningiomas: a retrospective study of 198 cases. J Neurosurg. 
2001;95(4):601–607.
28. Leone PE, Bello MJ, de Campos JM, et  al. NF2 gene mutations and 
allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene. 
1999;18(13):2231–2239.
29. Bello MJ, de Campos JM, Kusak ME, et al. Allelic loss at 1p is asso-
ciated with tumor progression of meningiomas. Genes Chromosomes 
Cancer. 1994;9(4):296–298.
30. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. 
Malignant progression in meningioma: documentation of a series and 
analysis of cytogenetic findings. J Neurosurg. 2004;101(2):210–218.
31. Boström J, Meyer-Puttlitz B, Wolter M, et  al. Alterations of the 
tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B 
(p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic men-
ingiomas. Am J Pathol. 2001;159(2):661–669.
32. Aizer AA, Abedalthagafi M, Bi WL, et al. A prognostic cytogenetic scor-
ing system to guide the adjuvant management of patients with atypical 
meningioma. Neuro Oncol. 2016;18(2):269–274.
33. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M. 
Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggres-
sive meningiomas and undifferentiated meningeal sarcomas. Cancer 
Genet Cytogenet. 1999;110(2):103–110.
34. Krayenbühl N, Pravdenkova S, Al-Mefty O. De novo versus trans-
formed atypical and anaplastic meningiomas: comparisons of clin-
ical course, cytogenetics, cytokinetics, and outcome. Neurosurgery. 
2007;61(3):495–503
35. Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. 
Brain Tumor Pathol. 2016;33(4):237–247.
36. Yuzawa S, Nishihara H, Yamaguchi S, et al. Clinical impact of targeted 
amplicon sequencing for meningioma as a practical clinical-sequencing 
system. Mod Pathol. 2016;29(7):708–716.
37. Zotti T, Vito P, Stilo R. The seventh ring: exploring TRAF7 functions. J Cell 
Physiol. 2012;227(3):1280–1284.
38. Bleeker FE, Felicioni L, Buttitta F, et  al. AKT1(E17K) in human solid 
tumours. Oncogene. 2008;27(42):5648–5650.
39. Tetreault MP, Yang Y, Katz JP. Krüppel-like factors in cancer. Nat Rev 
Cancer. 2013;13(10):701–713.
40. Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are 
as common as AKT1 and SMO mutations in meningioma. Neuro-Oncol. 
2016;18(5):649–655 . 
41. Reuss DE, Piro RM, Jones DT, et al. Secretory meningiomas are defined 
by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 
2013;125(3):351–358.
42. Sahm F, Bissel J, Koelsche C, et al. AKT1E17K mutations cluster with 
meningothelial and transitional meningiomas and can be detected by 
SFRP1 immunohistochemistry. Acta Neuropathol. 2013;126(5):757–762.
43. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in 
human cancers. Br J Cancer. 2006;94(4):455–459.
44. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations 
identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 
2005;102(3):802–807.
45. Christiaans I, Kenter SB, Brink HC, et al. Germline SMARCB1 mutation 
and somatic NF2 mutations in familial multiple meningiomas. J Med 
Genet. 2011;48(2):93–97.
46. Bacci C, Sestini R, Provenzano A, et al. Schwannomatosis associated 
with multiple meningiomas due to a familial SMARCB1 mutation. 
Neurogenetics. 2010;11(1):73–80.
47. Harmancı AS, Youngblood MW, Clark VE, et  al. Integrated genomic 
analyses of de novo pathways underlying atypical meningiomas. Nat 
Commun. 2017;8:14433.
48. Smith MJ, O’Sullivan J, Bhaskar SS, et al. Loss-of-function mutations in 
SMARCE1 cause an inherited disorder of multiple spinal meningiomas. 
Nat Genet. 2013;45(3):295–298.
49. Smith MJ, Wallace AJ, Bennett C, et al. Germline SMARCE1 mutations 
predispose to both spinal and cranial clear cell meningiomas. J Pathol. 
2014;234(4):436–440.
50. Raffalli-Ebezant H, Rutherford SA, Stivaros S, et  al. Pediatric intrac-
ranial clear cell meningioma associated with a germline mutation of 
SMARCE1: a novel case. Childs Nerv Syst. 2015;31(3):441–447.
51. Tauziede-Espariat A, Parfait B, Besnard A, et  al. Loss of SMARCE1 
expression is a specific diagnostic marker of clear cell meningioma: a 
comprehensive immunophenotypical and molecular analysis. Brain 
Pathol. 2018;28(4):466–474.
52. Collord G, Tarpey P, Kurbatova N, et al. An integrated genomic analysis 
of anaplastic meningioma identifies prognostic molecular signatures. 
Sci Rep. 2018;8(1):13537.
53. Wadt K, Choi J, Chung JY, et al. A cryptic BAP1 splice mutation in a fam-
ily with uveal and cutaneous melanoma, and paraganglioma. Pigment 
Cell Melanoma Res. 2012;25(6):815–818.
54. Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: 
implications for patient care. Neuro Oncol. 2017;19(11):1447–1456.
55. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 muta-
tion predisposes to uveal melanoma, lung adenocarcinoma, meningi-
oma, and other cancers. J Med Genet. 2011;48(12):856–859.
56. Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant 
mesothelioma. Transl Lung Cancer Res. 2017;6(3):270–278.
57. Koelsche C, Sahm F, Capper D, et  al. Distribution of TERT promoter 
mutations in pediatric and adult tumors of the nervous system. Acta 
Neuropathol. 2013;126(6):907–915.
58. Sahm F, Schrimpf D, Olar A, et al. TERT promoter mutations and risk of 
recurrence in meningioma. J Natl Cancer Inst. 2016;108(5):djv377.
59. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. 
High incidence of activating TERT promoter mutations in meningiomas 
undergoing malignant progression. Brain Pathol. 2014;24(2):184–189.
60. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification 
of central nervous system tumours. Nature. 2018;555(7697):469–474.
61. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 
2004;22(22):4632–4642.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/21/Supplem
ent_1/i4/5289366 by johns hopkins university user on 03 July 2019
 i16 Suppiah et al. Molecular landscape of sporadic meningiomas
62. Gao F, Shi L, Russin J, et al. DNA methylation in the malignant trans-
formation of meningiomas. PLoS One. 2013;8(1):e54114.
63. Bello MJ, Amiñoso C, Lopez-Marin I, et  al. DNA methylation of mul-
tiple promoter-associated CpG islands in meningiomas: relationship 
with the allelic status at 1p and 22q. Acta Neuropathol. 2004;108(5): 
413–421.
64. He S, Pham MH, Pease M, et al. A review of epigenetic and gene expres-
sion alterations associated with intracranial meningiomas. Neurosurg 
Focus. 2013;35(6):E5.
65. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. 
Hypermethylation and transcriptional downregulation of the TIMP3 
gene is associated with allelic loss on 22q12.3 and malignancy in men-
ingiomas. Brain Pathol. 2010;20(3):623–631.
66. Nakane Y, Natsume A, Wakabayashi T, et al. Malignant transformation-
related genes in meningiomas: allelic loss on 1p36 and methylation sta-
tus of p73 and RASSF1A. J Neurosurg. 2007;107(2):398–404.
67. Olar A, Wani KM, Wilson CD, et al. Global epigenetic profiling identifies 
methylation subgroups associated with recurrence-free survival in men-
ingioma. Acta Neuropathol. 2017;133(3):431–444.
68. Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classifi-
cation and grading system for meningioma: a multicentre, retrospective 
analysis. Lancet Oncol. doi:10.1016/S1470-2045(17)30155–9
69. Katz LM, Hielscher T, Liechty B, et al. Loss of histone H3K27me3 iden-
tifies a subset of meningiomas with increased risk of recurrence. Acta 
Neuropathol. 2018;135(6):955–963.
70. Saydam O, Shen Y, Würdinger T, et al. Downregulated microRNA-200a 
in meningiomas promotes tumor growth by reducing E-cadherin and 
activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol. 
2009;29(21):5923–5940.
71. Harmancı AS, Youngblood MW, Clark VE, et  al. Integrated genomic 
analyses of de novo pathways underlying atypical meningiomas. Nat 
Commun. 2017;8:14433.
72. Kliese N, Gobrecht P, Pachow D, et  al. miRNA-145 is downregulated in 
atypical and anaplastic meningiomas and negatively regulates motility and 
proliferation of meningioma cells. Oncogene. 2013;32(39):4712–4720.
73. Zhi F, Zhou G, Wang S, et al. A microRNA expression signature predicts 
meningioma recurrence. Int J Cancer. 2013;132(1):128–136.
74. Chen F, Xiang CX, Zhou Y, et al. Gene expression profile for predicting 
survival of patients with meningioma. Int J Oncol. 2015;46(2):791–797.
75. Olar A, Goodman LD, Wani KM, et  al. A gene expression signa-
ture predicts recurrence-free survival in meningioma. Oncotarget. 
2018;9(22):16087–16098.
76. Huang YC, Tsai YH, Lee JD, et al. Hemodynamic factors may play a crit-
ical role in neurological deterioration occurring within 72 hrs after lacu-
nar stroke. PLoS One. 2014;9(10):e108395.
77. Schulten HJ, Hussein D, Al-Adwani F, et al. Microarray expression data 
identify DCC as a candidate gene for early meningioma progression. 
PLoS One. 2016;11(4):e0153681.
78. Serna E, Morales JM, Mata M, et al. Gene expression profiles of meta-
bolic aggressiveness and tumor recurrence in benign meningioma. PLoS 
One. 2013;8(6):e67291.
79. Tabernero MD, Espinosa AB, Maillo A, et al. Patient gender is associated 
with distinct patterns of chromosomal abnormalities and sex chromo-
some linked gene-expression profiles in meningiomas. Oncologist. 
2007;12(10):1225–1236.
80. Schmidt M, Mock A, Jungk C, et al. Transcriptomic analysis of aggres-
sive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers 
independent of WHO grade. Oncotarget. 2016;7(12):14551–14568.
81. Okamoto H, Li J, Vortmeyer AO, et al. Comparative proteomic profiles of 
meningioma subtypes. Cancer Res. 2006;66(20):10199–10204.
82. Sharma S, Ray S, Mukherjee S, Moiyadi A, Sridhar E, Srivastava S. 
Multipronged quantitative proteomic analyses indicate modulation 
of various signal transduction pathways in human meningiomas. 
Proteomics. 2015;15(2–3):394–407.
83. Cui GQ, Jiao AH, Xiu CM, et al. Proteomic analysis of meningiomas. Acta 
Neurol Belg. 2014;114(3):187–194.
84. Saydam O, Senol O, Schaaij-Visser TB, et  al. Comparative protein 
profiling reveals minichromosome maintenance (MCM) proteins as 
novel potential tumor markers for meningiomas. J Proteome Res. 
2010;9(1):485–494.
85. Tufan K, Dogulu F, Kurt G, Emmez H, Ceviker N, Baykaner MK. Intracranial men-
ingiomas of childhood and adolescence. Pediatr Neurosurg. 2005;41(1):1–7.
86. Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic 
features in pediatric and NF2-associated meningiomas: a clinicopathologic 
study of 53 cases. J Neuropathol Exp Neurol. 2001;60(10):994–1003.
87. Arivazhagan A, Devi BI, Kolluri SV, Abraham RG, Sampath S, 
Chandramouli BA. Pediatric intracranial meningiomas–do they 
differ from their counterparts in adults? Pediatr Neurosurg. 
2008;44(1):43–48.
88. Hui M, Uppin MS, Saradhi MV, Sahu BP, Purohit AK, Sundaram C. 
Pediatric meningiomas an aggressive subset: a clinicopathological and 
immunohistochemical study. J Postgrad Med. 2015;61(1):32–35.
89. Dudley RWR, Torok MR, Randall S, et al. Pediatric versus adult meningi-
oma: comparison of epidemiology, treatments, and outcomes using the 
Surveillance, Epidemiology, and End Results database. J Neurooncol. 
2018;137(3):621–629.
90. Battu S, Kumar A, Pathak P, et  al. Clinicopathological and molecu-
lar characteristics of pediatric meningiomas. Neuropathology. 
2018;38(1):22–33.
91. Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ. 
Radiation-induced meningiomas: clinical, pathological, cytokinetic, and 
cytogenetic characteristics. J Neurosurg. 2004;100(6):1002–1013.
92. Godlewski B, Drummond KJ, Kaye AH. Radiation-induced men-
ingiomas after high-dose cranial irradiation. J Clin Neurosci. 
2012;19(12):1627–1635.
93. Lee JW, Wernicke AG. Risk and survival outcomes of radiation-induced 
CNS tumors. J Neurooncol. 2016;129(1):15–22.
94. Yamanaka R, Hayano A, Kanayama T. Radiation-induced meningiomas: an 
exhaustive review of the literature. World Neurosurg. 2017;97:635–644.e8.
95. Agnihotri S, Suppiah S, Tonge PD, et al. Therapeutic radiation for child-
hood cancer drives structural aberrations of NF2 in meningiomas. Nat 
Commun. 2017;8(1):186.
96. Lillehei KO, Donson AM, Kleinschmidt-DeMasters BK. Radiation-
induced meningiomas: clinical, cytogenetic, and microarray features. 
Acta Neuropathol. 2008;116(3):289–301.
97. Ueyama Y, Morita K, Ochiai C, Ohsawa N, Hata J, Tamaoki N. 
Xenotransplantation of a human meningioma and its lung metastasis 
in nude mice. Br J Cancer. 1978;37(4):644–647.
98. Rana MW, Pinkerton H, Thornton H, Nagy D. Heterotransplantation of 
human glioblastoma multiforme and meningioma to nude mice. Proc 
Soc Exp Biol Med. 1977;155(1):85–88.
99. Rath P, Miller DC, Litofsky NS, et al. Isolation and characterization of a 
population of stem-like progenitor cells from an atypical meningioma. 
Exp Mol Pathol. 2011;90(2):179–188.
100. Tanaka K, Sato C, Maeda Y, et  al. Establishment of a human malig-
nant meningioma cell line with amplified c-myc oncogene. Cancer. 
1989;64(11):2243–2249.
101. Püttmann S, Senner V, Braune S, et  al. Establishment of a benign 
meningioma cell line by hTERT-mediated immortalization. Lab Invest. 
2005;85(9):1163–1171.
102. Burns SS, Akhmametyeva EM, Oblinger JL, et al. Histone deacetylase 
inhibitor AR-42 differentially affects cell-cycle transit in meningeal 
and meningioma cells, potently inhibiting NF2-deficient meningioma 
growth. Cancer Res. 2013;73(2):792–803.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/21/Supplem
ent_1/i4/5289366 by johns hopkins university user on 03 July 2019
i17Suppiah et al. Molecular landscape of sporadic meningiomas
N
eu
ro-
O
n
colog
y
103. Mei Y, Bi WL, Greenwald NF, et al. Genomic profile of human meningi-
oma cell lines. PloS One. 2017;12(5):e0178322.
104. Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactiva-
tion in arachnoidal cells is rate-limiting for meningioma development in 
the mouse. Genes Dev. 2002;16(9):1060–1065.
105. Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, et  al. 
Meningioma progression in mice triggered by Nf2 and Cdkn2ab inacti-
vation. Oncogene. 2013;32(36):4264–4272.
106. Olson JJ, Beck DW, Schlechte JA, Loh PM. Effect of the antiprogester-
one RU-38486 on meningioma implanted into nude mice. J Neurosurg. 
1987;66(4):584–7.
107. Haase D, Schmidl S, Ewald C, et al. Fatty acid synthase as a novel tar-
get for meningioma therapy. Neuro Oncol. 2010;12(8):844–854.
108. Stepanova DS, Semenova G, Kuo YM, et al. An essential role for the 
tumor-suppressor merlin in regulating fatty acid synthesis. Cancer Res. 
2017;77(18):5026–5038.
109. Jensen RL, Wurster RD. Calcium channel antagonists inhibit growth 
of subcutaneous xenograft meningiomas in nude mice. Surg Neurol. 
2001;55(5):275–283.
110. Ragel BT, Gillespie DL, Kushnir V, Polevaya N, Kelly D, Jensen RL. 
Calcium channel antagonists augment hydroxyurea- and ru486-induced 
inhibition of meningioma growth in vivo and in vitro. Neurosurgery. 
2006;59(5):1109–20; discussion 1120.
111. Karsy M, Hoang N, Barth T, et  al. Combined hydroxyurea and ver-
apamil in the clinical treatment of refractory meningioma: human 
and orthotopic xenograft studies. World Neurosurg. 2016;86: 
210–219.
112. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT. 
Celecoxib inhibits meningioma tumor growth in a mouse xenograft 
model. Cancer. 2007;109(3):588–597.
113. Friedrich S, Schwabe K, Grote M, Krauss JK, Nakamura M. 
Effect of systemic celecoxib on human meningioma after intra-
cranial transplantation into nude mice. Acta Neurochir (Wien). 
2013;155(1):173–182.
114. Pachow D, Andrae N, Kliese N, et  al. mTORC1 inhibitors sup-
press meningioma growth in mouse models. Clin Cancer Res. 
2013;19(5):1180–1189.
115. Gupta V, Su YS, Samuelson CG, et  al. Irinotecan: a potential new 
chemotherapeutic agent for atypical or malignant meningiomas. J 
Neurosurg. 2007;106(3):455–462.
116. Takeda H, Okada M, Kuramoto K, et al. Antitumor activity of gemcit-
abine against high-grade meningioma in vitro and in vivo. Oncotarget. 
2017;8(53):90996–91008.
117. Nigim F, Esaki S, Hood M, et  al. A new patient-derived orthotopic 
malignant meningioma model treated with oncolytic herpes simplex 
virus. Neuro Oncol. 2016;18(9):1278–1287.
118. Ho WS, Sizdahkhani S, Hao S, et al. LB-100, a novel protein phosphat-
ase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the 
therapeutic effects of radiation. Cancer Lett. 2018;415:217–226.
119. Chow HY, Dong B, Duron SG, et al. Group I Paks as therapeutic targets 
in NF2-deficient meningioma. Oncotarget. 2015;6(4):1981–1994.
120. Zhai L, Ladomersky E, Lauing KL, et al. Infiltrating T cells increase IDO1 
expression in glioblastoma and contribute to decreased patient sur-
vival. Clin Cancer Res. 2017;23(21):6650–6660.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/21/Supplem
ent_1/i4/5289366 by johns hopkins university user on 03 July 2019
